ACRO Biomedical Co

ACRO Biomedical Co Gross Margin

The Gross Margin of ACRO Biomedical Co (6748.TWO) as of Nov 17, 2026 is 48.43 %. In the previous year, Gross Margin was 59.21 % — a change of -18.20% (lower).

Gross Margin

48.43 %

YoY

-18.20%

Last updated:

Gross Margin of ACRO Biomedical Co is 2025 48.43 % . Gross Margin of ACRO Biomedical Co was 2024 59.21 % . It decreases by -18.20% lower compared to the previous year.

For ACRO Biomedical Co, the gross margin of 48.4% is down versus 66.6% a few years ago.

The ACRO Biomedical Co Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
75.78 TWD
Jan 1, 2020
47.55 TWD
Jan 1, 2021
66.62 TWD
Jan 1, 2022
48.59 TWD
Jan 1, 2023
76.60 TWD
Jan 1, 2024
59.21 TWD
Jan 1, 2025
48.43 TWD
The ACRO Biomedical Co Gross Margin history
YEARGross MarginYoY
48.43 %-18.20%
59.21 %-22.71%
76.60 %+57.64%
48.59 %-27.06%
66.62 %+40.10%
47.55 %-37.25%
75.78 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ACRO Biomedical Co Stock analysis

What does ACRO Biomedical Co do? ACRO Biomedical Co., Ltd. generates revenue through the development and production of biomaterial medical devices, primarily focusing on collagen scaffolds for tissue engineering and regenerative medicine. The company offers products such as ABCcolla Collagen Bone Graft, ABCcolla Collagen Matrix, ABCcolla Collagen Matrix Powder, ABCcolla Scar Spray, and ABCcolla External Aesthetic Restoration Prosthesis, all derived from pig skin and pig bone. These products are sold to healthcare providers and medical institutions involved in tissue engineering and regenerative medicine procedures. The firm also engages in international trade and technical services related to its products, expanding its market reach beyond local healthcare sectors. The company's revenue streams are driven by the sale of its specialized collagen-based medical devices, which are designed for applications in tissue repair and aesthetic restoration. ABCcolla Collagen Bone Graft targets bone regeneration, while ABCcolla Collagen Matrix and its variants support soft tissue engineering. ABCcolla Scar Spray addresses scar management, and the External Aesthetic Restoration Prosthesis serves cosmetic and reconstructive needs. These products cater to medical professionals seeking advanced solutions in regenerative medicine. ACRO Biomedical's business model relies on direct sales to healthcare institutions and international trade channels. The firm's focus on pig-derived collagen products positions it as a supplier for tissue engineering applications, with a strong emphasis on regenerative medicine. Technical services complement product sales, enhancing customer retention and recurring revenue opportunities. The company's product portfolio is tailored to meet the specific demands of medical professionals in tissue repair and aesthetic restoration markets. ACRO Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ACRO Biomedical Co stock

Gross Margin of ACRO Biomedical Co is 48.43 % in 2025.

Gross Margin of ACRO Biomedical Co changed from 59.21 % to 48.43 %, representing a -18.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin ACRO Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's ACRO Biomedical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — ACRO Biomedical Co

All Key Metrics — ACRO Biomedical Co